Skip to search formSkip to main contentSkip to account menu

BNP 1350

Known as: BNP-1350, BNP1350, DB 172 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

cositecan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Karenitecin (BNP1350) radiosensitizes glioma cells with an associated increase in caspase activation and reactive oxygen species.
The prognosis for patients with high-grade glioma remains dismal illustrating the need for the development of chemotherapeutic… 
2016
2016
Karenitecin (bnp1350) and flavopridol as radiosensitizers in malignant glioma.
The poor prognosis of malignant glioma patients highlights the need to develop low toxicity, tumor specific agents with the… 
2006
2006
Gateways to clinical trials.
101M, 12B75; ABT-869, Agomelatine, Alvocidib hydrochloride, Amb a 1 ISS-1018, AMG-386, Andolast, AP-23573, Arsenic trioxide, ATI… 
Review
2005
Review
2005
Phase II Trial of Karenitecin in PatientswithMalignantMelanoma : Clinical andTranslational Study
Purpose: A phase II trial of the novel camptothecin karenitecin (BNP1350) was conducted to determine its efficacyand tolerability… 
2004
2004
Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates
PurposeBNP1350 (7-[(2-trimethylsilyl)ethyl]-20(S)-camptothecin, karenitecin), a highly lipophilic camptothecin, a high percentage… 
2004
2004
Phase II trial of karenitecin (BNP1350) in malignant: Clinical and translational study.
7554 Background: To determine the efficacy and safety of the novel camptothecin, karenitecin (BNP1350), in patients with… 
2002
2002
Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: Determination of efficacy and possible mechanisms of resistance
The novel camptothecin derivative BNP1350 (7‐[2‐trimethylsilyl)ethyl]‐20(S)‐camptothecin), also known as Karenitecin, has been… 
2002
2002
Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350.
Highly Cited
2000
Highly Cited
2000
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer
BNP1350, 7‐[(2‐trimethylsilyl)ethyl]‐20(S)‐camptothecin, is a novel semi‐synthetic, highly lipophilic, silicon‐containing… 
2000
2000
Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.
Cellular topoisomerase I is an important target in cancer chemotherapy. A novel karenitecin, BNP1350, is a topoisomerase I… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)